Novo Nordisk Financials

Novo Nordisk AS

NVONYSE

Trade with Public

$43.24

0.050.12%

al cierre: Sep 18, 5:00 PM EST

$43.34

0.09990.23%

After hour: Sep 18, 7:57 PM EST

Panorámica general Noticias Previsión de beneficios Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

Novo Nordisk Financials

Novo Nordisk (NVO) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Hims & Hers Health: Investments Necessary For Long-Term Incremental Growth, Says Bullish Analyst

HIMS stock edges lower after mixed Q2 results. Needham analyst maintains Buy rating, raises PT to $42. Company's revenue up 38.2% YoY.

Priya Nigam

PRO
Novo Nordisk Q2 Adj. EPS $0.96 Beats $0.81 Estimate, Sales $12.209B Beat $11.350B Estimate

Novo Nordisk (NYSE:NVO) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $0.81 by 18.52 percent. This is a 5.49 percent increase over earnings of $0.91 per share from the same

Benzinga Newsdesk

Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks

Novo Nordisk raises 2026 guidance as Wegovy pill tops 5 million U.S. prescriptions, but stock falls despite higher GLP-1 sales expectations.

Vandana Singh

PRO
Novo Nordisk Expects Outlook FY Adjusted Revenue Growth -6 To 0%; Q2 Adj Sales Up 7% At CER; Adj Operating Profit Up 11% At CER; Raises 2026 Adj Sales, Operating Profit Outlook To 0% To -6% At Cer; Improved Outlook Is Driven By Increased Expectations For Glp-1 Product Sales

Novo Nordisk today announced adjusted sales and adjusted operating profit for the second quarter of 2026 and raised 2026 full-year adjusted sales and adjusted operating profit outlook at CER.

Benzinga Newsdesk

Earnings Volatility Watch: SanDisk and Nine Other Stocks Could Swing Up To 17.5% This Week

SanDisk, Western Digital and eight other names carry the biggest implied earnings moves in the first week of August, led by the memory chipmakers.

Piero Cingari

Hims & Hers Health Posts Mixed Q1 Amid Weight-Loss Product 'Noise': Analysts

Hims & Hers Health shares tank after disappointing Q1 results. Company raised 2026 revenue outlook. EBITDA outlook was lowered by $25M.

Priya Nigam

Novo Nordisk AS

Novo Nordisk Financials

Earnings & Guidance News

Hims & Hers Health: Investments Necessary For Long-Term Incremental Growth, Says Bullish Analyst

PRO
Novo Nordisk Q2 Adj. EPS $0.96 Beats $0.81 Estimate, Sales $12.209B Beat $11.350B Estimate

Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks

PRO
Novo Nordisk Expects Outlook FY Adjusted Revenue Growth -6 To 0%; Q2 Adj Sales Up 7% At CER; Adj Operating Profit Up 11% At CER; Raises 2026 Adj Sales, Operating Profit Outlook To 0% To -6% At Cer; Improved Outlook Is Driven By Increased Expectations For Glp-1 Product Sales

Earnings Volatility Watch: SanDisk and Nine Other Stocks Could Swing Up To 17.5% This Week

Hims & Hers Health Posts Mixed Q1 Amid Weight-Loss Product 'Noise': Analysts

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Novo Nordisk AS

Novo Nordisk Financials

Earnings & Guidance News

Hims & Hers Health: Investments Necessary For Long-Term Incremental Growth, Says Bullish Analyst

PRONovo Nordisk Q2 Adj. EPS $0.96 Beats $0.81 Estimate, Sales $12.209B Beat $11.350B Estimate

Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks

PRONovo Nordisk Expects Outlook FY Adjusted Revenue Growth -6 To 0%; Q2 Adj Sales Up 7% At CER; Adj Operating Profit Up 11% At CER; Raises 2026 Adj Sales, Operating Profit Outlook To 0% To -6% At Cer; Improved Outlook Is Driven By Increased Expectations For Glp-1 Product Sales

Earnings Volatility Watch: SanDisk and Nine Other Stocks Could Swing Up To 17.5% This Week

Hims & Hers Health Posts Mixed Q1 Amid Weight-Loss Product 'Noise': Analysts

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

PRO
Novo Nordisk Q2 Adj. EPS $0.96 Beats $0.81 Estimate, Sales $12.209B Beat $11.350B Estimate

PRO
Novo Nordisk Expects Outlook FY Adjusted Revenue Growth -6 To 0%; Q2 Adj Sales Up 7% At CER; Adj Operating Profit Up 11% At CER; Raises 2026 Adj Sales, Operating Profit Outlook To 0% To -6% At Cer; Improved Outlook Is Driven By Increased Expectations For Glp-1 Product Sales